MedTrace Logo

Reference Values and Clinical Screening Test of Diffuse Noxious Inhibitory Controls (DNIC)

NCT03376867 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 468

Last updated 2024-02-15

No results posted yet for this study

Summary

Chronic pain (CP) is disabling for people triggering important costs for society. A deficit of diffuse noxious inhibitory controls (DNIC) is one of the CP mechanisms. DNICs are evaluated in research setting using a CPM protocol (conditioned pain modulation). There is a lack of reference values on the effectiveness of DNICs. Wider research on DNIC will help to understand CP and to develop a clinical screening test evaluating DNICs.

Conditions

Interventions

OTHER

Conditioned pain modulation

Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Centre for Research of CHUS (CRCHUS)

    collaborator UNKNOWN

  • CIHR/SPOR - chronic pain network

    collaborator UNKNOWN

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Louis Gendron, PhD · Université de Sherbrooke

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-27
Primary Completion
2022-02-28
Completion
2024-12-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03376867 on ClinicalTrials.gov